|

XNW5004 Clinical Trials

2 actively recruiting trials

Also known as: EZH2i

Pipeline

Phase 1/2: 2

Top Sponsors

  • Evopoint Biosciences Inc.2

Indications

  • Cancer2
  • mCRPC (Metastatic Castration-resistant Prostate Cancer)1
  • Metastatic Castrate-Resistant Prostate Cancer1
  • Other Solid Tumors1
  • Squamous Cell Carcinoma of Head and Neck1

Other2 trials

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase 1/2
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.